Maxim analyst Jason McCarthy downgraded Cero Therapeutics (CERO) to Hold from Buy.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Why Is CERo Therapeutics Stock Down 80% Today?
- CERo Therapeutics Faces Nasdaq Delisting Suspension
- Cero Therapeutics discloses Nasdaq Panel listing determination
- Cero Therapeutics’ Innovative AML Treatment Study: A Potential Game-Changer?